Not for distribution to U.S. Newswire Services or for dissemination in the United States.
INDIVA Announces Incentive Stock Options
LONDON, ON – (May 30, 2018): INDIVA Limited (the “Company” or “INDIVA“) (TSX-V:NDVA) is pleased to announce that the Company has granted 350,000 incentive stock options (the “Options“) to certain employees.
The Options have an exercise price of $0.80 per share and will be valid until May 30, 2023.
The Company’s Stock Option Plan allows for the issuance of up to 10% of issued and outstanding share capital in the form of incentive stock options. As a result of this grant, the Company has a total of 4,668,315 stock options issued, representing 5.8% of the issued and outstanding share capital.
INDIVA is further pleased to announce it has retained Mackie Research Capital Corp. (“Mackie“) for an initial three-month term, ending July 31, 2018, to provide market stabilization and liquidity services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (“TSX-V“) and other applicable legislation.
Mackie will trade common shares of the Company (“Shares“) on the TSX-V for the purposes of maintaining a reasonable market and improving the liquidity of the Shares. The agreement between Mackie and the Company may be terminated by either party upon written notice.
Mackie will be paid $3,500 per month, payable quarterly in advance. Mackie and INDIVA are at arm’s length. Mackie will, from time to time, acquire up to $30,000 in Shares to facilitate its market-making activities. The funds and securities required for the market-making activities will be provided by Mackie.
Further information about Mackie can be found at: www.mackieresearch.com.
INDIVA is a Canadian supplier of high quality, medical grade cannabis. INDIVA’s strain selection, cultivation and client care processes combine the know-how and experience of an internationally recognized and award-winning grow-team with GMP-compliant quality assurance standard operating procedures.
INDIVA’s wholly owned subsidiary is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulation (“ACMPR“) with its first indoor cannabis production facility located in London, Ontario.
INDIVA aims to become a global marijuana brand recognized for high quality cannabis products and excellent client care. As marijuana laws liberalize in Canada, INDIVA will expand its product offering to include safe edibles and other client-friendly cannabis products. In addition, as marijuana laws liberalize internationally, INDIVA will use its Canadian operations as a platform to open new markets for its cannabis products.
Niel Marotta, CEO
Email: [email protected]
Steve Low, Investor Relations
Email: [email protected]
DISCLAIMER & READER ADVISORY
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the Transaction and neither of the foregoing entities accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The business of the Company is subject to a number of material risks and uncertainties. Please refer to the Filing Statement of the Company and other SEDAR filings for further details. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The forward looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.